Oslo, 15. February 2016: Serodus ASA is pleased to announce that the European Patent Office (EPO) has approved the patent application No. PCT/DK2012/000022 (12710122.8) covering the peptide SER140. 

The patent protects the SER140 peptide and various related amino acid sequences in treatment of different diseases caused by inflammatory processes (e.g. diabetes, rheumatoid arthritis, Sjögren’s disease and Systemic lupus erythematosus).

Data recently published in Journal of Diabetes Research showed that 8 weeks of treatment with SER140 significantly reduced the incidence of diabetes, decreased blood glucose and increased plasma insulin in female non-obese diabetic (NOD) mice.

Eva Steiness, CEO of Serodus, commented: “This European patent is the first granted for SER140 while patent applications are pending in most other countries. Patents are very important in the protection of the SER140 peptide, which recently showed very interesting effects in a disease-relevant test model. Serodus continues the non-clinical development of SER140”.


For more information contact:

Tore Kvam

CFO, Serodus ASA

Mobile: +47 959 34 199


Serodus ASA is a Norwegian drug development company, focusing on new therapeutic products for the treatment of cardiovascular and metabolic diseases with large unmet clinical needs. The company's business model is to seek partnering with international pharmaceutical companies after having demonstrated clinical effect in humans. For more information see